Lose Up To
15% of Body Weight
With GLP-1*
Weight Loss
Made Easy With
with a Semaglutide Prescription
Clinically proven weight-loss solution
Affordable, competitive pricing
*With consistent, recommended use. Results may vary. In a 68-week clinical trial studying once-weekly semaglutide (2.4mg) in patients without diabetes and with BMI ≥30, or BMI ≥27 with a weight-related condition, the average weight loss was 15% when paired with lifestyle intervention (compared to 2.4% with lifestyle intervention alone).⁵
Reach Your Goal of Better Health in 3 Simple Steps
1
Health Questionnaire
Answer a few questions to help us understand your health concerns and medical history.
2
Doctor Approval
A licensed U.S. physician will review your account and determine eligibility to create a personalized treatment plan.
3
Quick Delivery
Once approved, our partner pharmacy will receive your prescription and ship your medication in as little as 3 days.
Ready to lose weight?
See if I qualify
The Truth About GLP-1 Medication
Make you feel fuller for longer¹
Keep sugar spikes at bay²
Reduce inflammation³
Slow down digestion⁴
See if I qualify
Key Weight Loss Benefits of GLP-1
Appetite Regulation
GLP-1 medications target the brain's appetite-regulating centers, helping individuals eat less, especially after meals.
Long-Term Efficacy
In clinical studies, patients on GLP-1s are able to lose weight, modify eating habits, and maintain a healthier BMI.
Prolonged Fullness
By slowing stomach emptying, GLP-1s promote satiety (fullness), decrease appetite, and reduce the amount of food you eat.
Significant Weight Loss
In clinical trials, patients on GLP-1s have been shown to lose up to 15%* of body weight over a period of 6-8 months.
Frequently Asked Questions
How much does it cost?
Price varies by medication, with plans starting as low as $299/month.
How much weight will I lose?
Actual weight loss will vary per individual. Many GLP-1 patients can expect to lose 5% of their initial body weight but may lose up to 20% or more. Everyone is different and most success can be attributed to consistency, healthy habits, and dietary adjustments. Keep in mind that extreme weight loss is not a medically safe or desired effect. Healthy weight loss can be defined as losing 1 to 2 lbs per week.
Are GLP-1 medications safe?
Yes, GLP-1 medications are well-studied and effective treatments for weight loss. Specific precautions will be discussed with you by your Remote Pharmacy provider. The most common side effects of semaglutide may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.
How do I inject my medication?
Subcutaneous injections will be explained by your provider. Always consult with your provider or licensed medical professional if you have any questions.
You can also find our in-depth guide for preparing and injecting your medication here: https://remotepharmacy.com/instructions.php
Who are Remote Pharmacy's partner pharmacies?
Our Pharmacy Hub is located at 15600 NW 15th Ave, Miami, FL 33169. They can be contacted at (954) 483-6957. They maintain a license in 50 US states. Unfortunately, they cannot dispense sterile compounds in the following U.S. states: LOUISIANA, MISSISSIPPI, and NEW MEXICO.
Our partner pharmacy, GoGo Meds DBA Jungle Jims is located at 5484 Dixie Highway, Fairfield, OH 45014. They can be contacted at (877) 858-3784. They maintain a license in 44 US states.
Unfortunately, GoGo Meds DBA Jungle Jims cannot dispense sterile compounds and do not have a license in the following U.S. states: CALIFORNIA, DELAWARE, MASSACHUSETTS, MISSISSIPPI, NEVADA, NEW HAMPSHIRE, NEW JERSEY, NORTH CAROLINA, TEXAS, and WEST VIRGINIA.
Who are Remote Pharmacy's providers?
Our clinical providers are Beluga Health c/o Jonah Mink MD. Feel free to contact them at info@belugahealth.com. Beluga Health, P.A., a Florida professional corporation, has its office located at 1321 Upland Dr., Suite 18399, Houston, TX, 77043.
Powered By
© 2024 RemotePharmacy
1 Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998). Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. Journal of Clinical Investigation, 101(3), 515–520.
2 Nauck, M. A., Meier, J. J., & Cavender, M. A. (2017). Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation, 136(9), 849-870.
3 Drucker, D. J. (2016). The cardiovascular biology of glucagon-like peptide-1. Cell Metabolism, 24(1), 15-30.
4 Herrmann, C., & Goke, R. (2007). The incretin concept today. Diabetologia, 50(8), 1794-1803.
5 Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183